Bristol-Myers Squibb (BMY) Tops Q2 EPS by 40c; raises guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.46, $0.40 better than the analyst estimate of $1.06. Revenue for the quarter came in at $12.27 billion versus the consensus estimate of $11.34 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2025 EPS of $6.35-$6.65, versus the consensus of $6.32. Bristol-Myers Squibb sees FY2025 revenue of $46.5-47.5 billion, versus the consensus of $46.265 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
• Purebread Brands to acquire Caffè Artigiano in a $7.7M share deal
• Lockheed Martin (LMT) Raises Quarterly Dividend 4.3% to $3.60; 2.8% Yield